Innovations in group‐based psilocybin‐assisted therapy of major depression in patients with cancer
Johannes Thrul, Zofia Kozak, Michael A. Carducci, Albert Garcia‐romeu, David B. Yaden
Cancer December 18, 2023 DOI: 10.1002/cncr.35127 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractPsilocybin, when administered in a group-based, assisted intervention, shows promise for treating depression in cancer patients. Two articles in Cancer report that this approach leads to persistent improvements in mood, building on earlier work that found psilocybin reduces existential distress in this population. The editorial discusses these findings, noting the positive effects on mood without specifying effect sizes or sample details.
Study at a glance
| Characteristics | Editorial Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Cancer Depression economics Mood Distress |
| Citations | 5 |
| Key finding | Argues that group-based psilocybin-assisted intervention may be a novel therapeutic approach for treating depression in cancer patients. |
Abstract
Several recent studies have investigated psilocybin as a novel therapeutic compound for the treatment of existential distress in patients with cancer, demonstrating persistent, positive effects on mood. This editorial discusses two articles in the current issue of Cancer that report findings of a group‐based psilocybin‐assisted intervention for treatment of depression in patients diagnosed with cancer.